UFP Technologies, Inc. (UFPT) Earnings
UFP Technologies, Inc. is expected to report next earnings on November 2, 2026 (in NaN days), with a consensus EPS estimate of $2.63. UFPT has beaten EPS estimates in 10 of its last 12 reported quarters (average surprise +13.2% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 4, 2026 | $2.31 | $2.69 | +16.5% | $174M | +9.1% |
| May 5, 2026 | $2.18 | $2.48 | +13.8% | $154M | -0.4% |
| Feb 25, 2026 | $2.26 | $2.44 | +8.0% | $149M | -3.6% |
| Jul 31, 2024 | $1.53 | $1.75 | +14.6% | $110M | +3.0% |
| May 1, 2024 | $1.10 | $1.64 | +49.1% | $105M | +7.2% |
| Feb 21, 2024 | $1.18 | $1.51 | +27.5% | $101M | +6.4% |
| Nov 1, 2023 | $1.52 | $1.52 | +0.2% | $101M | +4.5% |
| Aug 1, 2023 | $1.47 | $1.55 | +5.7% | $100M | -0.9% |
| May 2, 2023 | $1.04 | $4.20 | +303.8% | $98M | +7.7% |
| Mar 7, 2023 | $0.90 | $1.10 | +22.0% | $91M | +4.7% |
| Nov 2, 2022 | $0.94 | $0.51 | -46.0% | $97M | +14.5% |
| Aug 2, 2022 | $0.74 | $1.17 | +58.1% | $94M | +25.2% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q2 FY2026 · August 4, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
- New CEO Transition: Mitch Rock began his tenure as President and CEO, confirming the company's long-standing strategy will remain unchanged, with core priorities of supporting customers, investing in team and operational capabilities, pursuing disciplined acquisitions, and delivering long-term shareholder value. - Capacity and Investment Progress: The company continues to invest in new manufacturing capacity in the Dominican Republic (DR) to support customer growth, expand total capacity, and improve long-term cost structure. Early operational benefits have been realized, though full benefit delivery is taking longer than initially planned. Two of three planned program transfers to the DR have been completed, with the third still pending customer qualification. The company has also added new leadership roles across business development, operations, and legal to build organizational capacity for its next growth phase, supporting onboarding of future acquisitions under the company's decentralized operating model. - Acquisition Strategy: The company's disciplined acquisition strategy remains unchanged, with a robust pipeline of potential targets focused on expanding capabilities and strengthening position in attractive MedTech end markets. Management remains committed to deploying capital only in opportunities that deliver long-term shareholder value. - Operational Backlog Resolution: The prior backlog and labor issues at AJR have been fully resolved, and AJR's St. Charles facility is now fully ramped, with the business continuing to grow significantly.
Guidance
- Management did not provide explicit full-year 2026 financial guidance, but confirmed that after the double-digit 12.4% organic growth in Q2 2026 (which benefited from a very weak comparably period in Q2 2025, when AJR faced significant labor inefficiencies), organic growth for the remainder of 2026 is expected to fall back into the company's long-term target range of 6% to 9%. - Two new robotic assisted surgical programs launched in 2026 are currently ramping as planned, and are expected to deliver an eight-figure annual revenue contribution as they grow into 2027. - The elevated current SG&A level is expected to be the new baseline going forward, with only minor temporary relief from one-time CEO transition costs expected in mid-2027.
Segment performance
Overall company Q2 2026 total sales were $174 million, an increase of 15.1% year-over-year. Organic sales grew 12.4% year-over-year. Growth was led by strength in the surfaces and support, cardiovascular, infection control, and orthopedics submarkets of the company's core MedTech business. The top five customers accounted for 61% of year-to-date total sales, growing 14.7% year-over-year, while the remainder of the MedTech business grew 19.7% year-over-year. Gross margin increased to 29.3% from 28.8% year-over-year. Operating income grew 15.5% year-over-year. Adjusted operating margin was 17.6% of sales, and adjusted EPS grew 16.8% year-over-year to a company record $2.92. SG&A expenses increased $4.1 million year-over-year to $22.8 million. Operating cash flow was $15.6 million, and capital expenditures were $1.2 million. The company's ending leverage ratio was below 1.0x.
Risks & headwinds
- Volatile oil prices driven by the ongoing conflict in Iran have led to continued inflationary increases for the company's petroleum-based raw material inputs. The ultimate magnitude of cost increases is uncertain due to daily changes in the geopolitical environment and oil market volatility. - The timeline for transferring remaining production to the Dominican Republic is controlled by customer qualification requirements, creating uncertainty around when the full cost and capacity benefits of the new facility will be realized. - Forward-looking financial and operational statements are inherently subject to risks and uncertainties that could cause actual results to differ materially from management's current expectations, with further detail available in the company's recent SEC filings.
Analyst Q&A
Q: After the strong Q2 revenue growth, can you share more detail on underlying market trends and drivers of the strong performance, including the AJR backlog and progress of planned 2026 new program launches? /
A: Growth was broad-based across core MedTech end markets including cardiovascular, infection control, patient handling, and orthopedics, while robotic surgical markets remained flattish as expected. The prior AJR backlog has been fully cleared, and that business continues to grow significantly. Of the four programs previously cited as launching in 2026, only three are net new external programs, and their contribution to Q2 growth was in line with expectations. Most Q2 growth came from expansion of existing customer relationships and product lines, not new program launches. (698 chars)
Q: Is the current elevated SG&A level the new baseline going forward, and can you share details on your current acquisition pipeline? /
A: The current SG&A level is approximately the new long-term baseline after recent organizational investments, with only minor temporary relief from one-time CEO transition costs expected to cycle through in mid-2027. The company currently has a robust pipeline of 5 to 10 acquisition targets, with target EBITDA ranging from $5 million to $30 million, aligned with the company's strategic focus on expanding MedTech capabilities. (487 chars)
Q: Now that the AJR backlog is resolved, have labor issues been fully resolved, and what is the status of production transfers to the Dominican Republic? /
A: Labor issues at AJR are fully resolved, and the St. Charles facility is fully ramped, with the platform continuing to grow. Of the three programs originally planned for transfer to the DR, two have been completed, and the third remains in process, pending customer qualification, which controls the timeline for transfer. (327 chars)
Q: Can you share an update on the two new robotic surgical programs announced last November, and their expected contribution? /
A: The two robotic assisted surgical programs have launched and are ramping on track. They are expected to deliver an eight-figure annual revenue contribution that will grow, with more meaningful contributions beginning in 2027. (214 chars)